Navigation Links
Lawson scientist presents joint pain treatment 2.0
Date:8/12/2011

LONDON, ON Osteoarthritis (OA) is the most common form of arthritis, affecting roughly 10% of Canadians. This degradation of the joints is painful and crippling, especially when it affects the knee. Although there are viable OA treatment options, they are short-lived and can have serious side-effects. According to Lawson Health Research Institute's Dr. Robert Petrella, principal investigator in the COR1.0 study, the next generation of OA treatment has arrived.

When patients have OA in the knee, the fluid in their joint breaks down, causing pain and preventing natural shock absorption. To treat this condition, gel-like substances called "viscosupplements" are injected into the knee. This acts as a supplement for the fluid loss and provides temporary pain relief. In the COR1.0 study, Dr. Petrella and his colleagues compared Synvisc-One, the leading market viscosupplement for OA in the knee, to Hydros-TA Joint Therapy. Hydros-TA is a unique dual-action treatment combining steroids within a viscosupplement. It is believed to provide faster acting, longer lasting pain relief than either treatment alone.

To compare and evaluate the safety and effectiveness of both treatments, Dr. Petrella and his team conducted a double-blinded, multi-center clinical trial. Across eight sites in Canada, Belgium, and The Netherlands, a total of 98 patients were given a single injection and then monitored for six months. Results show trends suggesting Hydros-TA provides superior pain relief and improved function, causes fewer adverse events, and has a higher overall response rate. For patients, this could mean greater, more consistent pain relief with faster onset.

"Patients are really searching for better options for osteoarthritis therapy," Dr. Petrella explains. "Hydros-TA takes effect very quickly and lasts longer than other available therapies, allowing patients to achieve and sustain a higher quality of life."

Dr. Petrella and Carbylan BioSurgery Inc., the makers of Hydros-TA, are planning a larger multi-center trial to take place in the United States next year.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related medicine news :

1. Scientists explore the intersection of health, society and microbial ecology
2. Scientists explain unique activity of TB drug pyrazinamide
3. BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
4. USC scientist develops virus that targets HIV
5. Scientists Take Navel-Gazing to New Level
6. Johns Hopkins scientists map genes for common form of brain cancer
7. Scientists May Have Found Missing Link to Common Brain Cancer
8. Have we met before? Scientists show why the brain has the answer
9. Scientists Warn of New Multidrug-Resistant Salmonella
10. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
11. Scientists show swamp gas protects blood vessels from complications of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... and Collaboration Platform™ , today announced a new Residency Education & Collaboration ... to medical knowledge, educational resources, and a host of collaboration tools designed ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... been named a Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. ... Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across the country. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... announced it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s ... at Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference and ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... The ... Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for separate ... medical community effective October 1, 2016. , Sarcopenia is defined as a combination of ...
(Date:4/28/2016)... ... April 28, 2016 , ... Boston Laser is now ... Drug Administration (FDA). The treatment consists of the application of Riboflavin, a vitamin, to ... fibers which in turn strengthens the cornea to slow the progression of keratoconus. , ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 Tie-up ... initiative to save newborns   ... women & newborns in collaboration with Breast Milk Foundation (BMF), ... first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This ... food source for infants and should be available to babies ...
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, Inc. ... Jennifer Hagerman , Pharm D., to Vice President ... role at Diplomat, Hagerman will continue to lead and ... that delivers custom education and training to Diplomat employees ... pharmacy industry. Diplomat University also houses the quality assurance ...
Breaking Medicine Technology: